Women's Global Impact Forum 2025 Live Updates: WNBA, Hulken, Nissan Leaders Connect
Newsweek's inaugural Women's Global Impact Forum on Tuesday, August 5, will bring together women in senior leadership with the "rising stars" across industries at Newsweek headquarters in New York City. Speakers and attendees will discuss the progress we've made and share actionable solutions to navigate the remaining challenges facing women in the business world.
The one-day event is sponsored by MyEyeDr., with partners Hers and STARZ.
Panels will feature discussions about navigating the entrepreneurial ecosystem, equity and inclusion, consumer engagement, redefining metrics of success, adopting AI, fostering creativity and the "post-girlboss" leaders of the next generation.
Notable speakers include Lo Bosworth, founder of Love Wellness; WNBA Commissioner Cathy Engelbert; SoulCycle CEO Evelyn Webster; and Indra K. Nooyi, former chairman and CEO of PepsiCo.
Other speakers represent companies such as Girl Scouts of the USA, NFL, Ring Concierge, Clinique, Ford Motor Company, WeightWatchers and Virtua Health.
Find the full schedule and list of speakers here.
Women's Global Impact: Generic Thumbnail
Women's Global Impact: Generic Thumbnail
Newsweek Illustration
Follow Newsweek's live blog for the latest updates.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
5 hours ago
- Newsweek
Dairy Queen Announces Major Menu Change Starting This Month
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Dairy Queen revealed its highly anticipated fall 2025 menu lineup, reintroducing the popular Pumpkin Pie Blizzard and debuting two desserts for customers nationwide. The new menu is set to launch across participating U.S. locations on August 29, for a limited time. Why It Matters Dairy Queen's seasonal menu updates have become a widely anticipated event, as the fast-food industry heightens its focus on limited-time flavors that help drive customer visits as seasons change. With ongoing competition from major brands like Krispy Kreme and Starbucks, which have both already announced pumpkin-inspired fall offerings, Dairy Queen aims to capture early fall attention and reinforce customer loyalty. Patrons are shown at a Dairy Queen restaurant amid the coronavirus pandemic, on May 25, 2020, in Williams, Arizona. Patrons are shown at a Dairy Queen restaurant amid the coronavirus pandemic, on May 25, 2020, in Williams, To Know The return of the Pumpkin Pie Blizzard, a dessert introduced in 1991, underscores the nostalgic appeal that has become a staple of fast-food seasonal menus. It has been consistently popular among Dairy Queen customers. The seasonal offering combines soft serve with pieces of real pumpkin pie and is finished with whipped cream and a sprinkle of nutmeg. Despite past years including other notable Blizzards, like the Oreo Fudge Brownie and Reese's Peanut Butter Cup Pie, the 2025 fall menu focuses on the Pumpkin Pie Blizzard as its main returning feature. Dairy Queen Reveals Two New Desserts Dairy Queen's 2025 Fall Treat Collection also features two brand-new items: Caramel Toffee Cookie Blizzard: This treat combines Dairy Queen's traditional soft serve with chewy cookie pieces, rich caramel and toffee. This treat combines Dairy Queen's traditional soft serve with chewy cookie pieces, rich caramel and toffee. Maple Cookie Shake: The shake features a maple cookie crumble base blended with soft serve and real milk, topped with whipped cream for a seasonal finish. The fall desserts will also be released nationwide at participating Dairy Queen locations on August 29. The company said these flavors will only be available for a limited time and encourage customers to visit stores before supplies run out. Current summer classics, including the Dipped Strawberry Cheesecake Blizzard and S'mores Blizzard, remain available for those not ready to welcome fall just yet. Newsweek reached out to Dairy Queen for comment via email. What People Are Saying Kevin Thompson, CEO of 9i Capital Group and host of the 9innings podcast, told Newsweek: "The fast-food industry continues to face rising costs, especially for staples like meat and chicken. To offset this, chains are leaning into higher-margin products. Ice cream and dessert items, like Dairy Queen's Blizzards, offer better profitability while also tapping into nostalgia. By bringing back fan favorites, Dairy Queen isn't just appealing to sentiment. It's strategically boosting margins in a challenging cost environment." Alex Beene, financial literacy instructor for the University of Tennessee at Martin, told Newsweek: "There's more to this strategy than Dairy Queen cashing in on the pumpkin craze so many other retailers do as the fall months approach. Dairy Queen, like other fast food restaurants, are pushing new menu items in an attempt to win back customers who have stopped eating out as much to save money. The hope is these new items can generate a buzz, increase foot traffic, and ultimately produce more sales." What Happens Next Dairy Queen's 2025 Fall Treat Collection officially rolls out August 29 at participating locations nationwide, remaining on menus for a limited time while supplies last.
Newsweek
9 hours ago
- Newsweek
Donald Trump Threatens 250% Tariff on Pharmaceuticals
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump has said that tariffs on pharmaceutical imports could eventually reach up to 250 percent, as his administration works to lower prescription prices for Americans. During an interview with CNBC on Tuesday, the president said he will initially impose a "small tariff on pharmaceuticals," which will rise to 150 percent "in one year, one and a half years maximum," before then eventually jumping to 250 percent. Newsweek reached out to the White House via email for comment. Why It Matters The United States imports a significant amount of pharmaceuticals each year—over $200 billion in 2024, according to the Observatory of Economic Complexity. Should Trump follow through on ramping up these duties, the highest he has threatened on the industry to date, experts believe this could result in significant increases to drug prices in the U.S. However, some health policy experts told Newsweek this could also help rebalance the global drug supply chain to better favor American customers. What To Know Trump said that the tariffs are intended to encourage pharmaceutical companies to move their operations to the U.S.—"because we want pharmaceuticals made in our country"—and to minimize reliance on Europe. He had previously threatened to place 200 percent tariffs on pharmaceuticals in July, but said he would give the industry time before this change came into effect. Trump's threats of pharmaceutical tariffs have raised concerns among experts that these could lead to increased costs and medication shortages in the U.S. In April, the UNC Center for the Business of Health published a report warning that these effects would be especially significant for generic drugs, which are more likely to be imported and operate on lower profit margins than brand-name medications. "A 250 percent tariff on pharmaceuticals would have a significant impact on drug prices," said health economist Jeromie Ballreich. Ballreich told Newsweek that, for branded pharmaceuticals, higher costs from the tariffs will be "passed on to consumers and most likely will be indirect through higher prescription drug insurance premiums." Major pharmaceutical companies across the world saw their shares fall on Wednesday following Trump's announcement. England-based AstraZeneca was down by 1.1 percent, Indiana-based Eli Lilly by 2.3 percent, and Germany-based Bayer AG by nearly 10 percent as of 11:20 ET. President Donald Trump speaks to reporters near Air Force One at Lehigh Valley International Airport on August 3, 2025. President Donald Trump speaks to reporters near Air Force One at Lehigh Valley International Airport on August 3, latest threat comes as the industry braces for the outcome of an ongoing probe by the Commerce Department into the national security implications of America's medicinal imports. The investigation was launched in April by Commerce Secretary Howard Lutnick under Section 232 of the 1962 Trade Expansion Act. Trump did not provide many specifics, such as whether certain classes of pharmaceuticals would be exempt, beyond stating that these tariffs are separate from the country-specific duties that came into effect last week. However, the announcement appears to contradict the terms of the European Union deal struck in July, which the European Commission president said placed a 15-percent tariff "ceiling" on multiple sectors, including pharmaceuticals. Experts had already warned that the 15 percent tariff outlined in the EU trade deal could end up costing the pharmaceutical industry billions. The cost implications could also be seen as conflicting with the administration's separate attempts to lower the price of prescription drugs. President of the European Commission Ursula von der Leyen meets with President Donald Trump in Turnberry, Scotland, on July 27, 2025. President of the European Commission Ursula von der Leyen meets with President Donald Trump in Turnberry, Scotland, on July 27, May, Trump signed an executive order directing the Secretary of Commerce and U.S. Trade Representative to "ensure foreign countries are not engaged in practices that purposefully and unfairly undercut market prices and drive price hikes in the United States." It also proposed that the U.S. be given Most-Favored-Nation (MFN) status, which would require drug companies to offer Americans the same lowest price that drugs are sold for in other countries. Trump followed this up by sending letters to 17 of the world's largest pharmaceutical companies on July 31, outlining steps they must take within 60 days to lower prescription prices for U.S. customers. These include extending MFN pricing to Medicaid, guaranteeing MFN pricing for new medications and negotiating "harder with foreign freeloading nations." The letters also call on the companies to expand direct-to-consumer distribution models to ensure customers "get the same low MFN prices that manufacturers already offer to third-party payers." "At face value, these tariffs are contradictory to his efforts to lower domestic prices," Ballreich told Newsweek. "However, if the tariffs are used as a threat to get drug companies to comply to his administration's [executive orders], including the recent letters to pharmaceutical CEOs, then I think we could see some changes to the pharmaceutical market, which will lower domestic drug prices." Several drugmakers, including Eli Lilly, AstraZeneca and Johnson & Johnson, have also pledged to expand their U.S. manufacturing presence. Prior to the letters being sent, but amid this pressure from the administration, a number had also announced they would be reducing some U.S. drug prices. Health policy analyst Mariana Socal warned that beyond potential cost implications, the tariffs could significantly disrupt the drug development pipeline, potentially jeopardizing the release of new medications. "Aside from the problem of added costs, the uncertainty introduced by tariff policies is detrimental in and of itself to the pharmaceutical market," she told Newsweek, noting that only around one in 10,000 investigated compounds make it to pharmacy shelves, and only do so after decades of work. "Any added uncertainty is likely to be detrimental to this industry, including disincentivizing investors from supporting this industry and pharmaceutical manufacturers from continuing to look for cures," she said. What People Are Saying Health economist Jeromie Ballreich told Newsweek: "This tariff could really disrupt the U.S. prescription drug market, especially the Medicare part D market, where the party plans will be on the hook for the higher price prices and result in significant premium increases to offset these higher prices. Given that, I don't think it's likely that this massive tariff will occur, but rather is a threat to force companies to find solutions based on the executive orders and his recent letters to pharmaceutical CEOs." Mariana Socal, an associate professor at the Johns Hopkins Bloomberg School of Public Health, told Newsweek: "It is critical to continue to identify solutions to lower drug prices in America and improve drug affordability for Americans. However, it is unclear how tariffs would advance affordability. On the opposite, tariffs can be understood as a hidden tax." "In the short term, the likelihood that added costs from tariffs will be passed through to consumers can be reduced by existing contractual agreements with supply chain participants such as distributors and group purchasing organizations, which can protect buyers from price increases for 1-3 years," she added. "However, even if the added cost of tariffs would not necessarily be passed-through to patients in the short term, it could raise costs in the long run." What Happens Next On Sunday, Trump said he would be announcing tariffs on the industry "within the next week or so."
Black America Web
12 hours ago
- Black America Web
Whiskey Industry Shifts In Kentucky, With Some Distillers Declaring Bankruptcy
Kentucky has long hedged its bets on its revered whiskey industry, which, according to the Kentucky Distillers' Association, brings in around $9 million a year. With the whiskey industry shifting along with changing habits of imbibers, some Kentucky distillers have declared bankruptcy, while others are reporting slowed sales. A new report from Newsweek highlighted some of the struggles the whiskey industry in Kentucky is facing of late, emphasizing the financial woes of Luca Mariano Distillery, which just filed for Chapter 11 under its LMD Holdings business name. The outlet, speaking with the Distilled Spirits Council of the United States, obtained a statement from the association, which reads in part that the 'hardships facing distilleries are not unique to those just in Kentucky.' The statement rings true as there has been a trend among the younger generations of abstaining from drinking and preferring a 'dry' lifestyle by ditching booze, sometimes in favor of going 'California Sober,' which points to the ingestion of THC-based drinks. The non-alcoholic drink trend, also widely stylized as NA drinks, has exploded as a category over the past few years. We care about your data. See our privacy policy. According to the publication, Luca Mariano Distillery launched its operation just this past June and is housed on a 553-acre estate in the town of Danville. Francesco Viola, the brand's owner, told a local outlet, the Lexington Herald-Leader , that the filing is a strategy to solidify long-term success for the distillery. Other companies, such as Garrard County Distilling, are struggling as well after it was reported that the Lancaster-based brand was put under receivership and shuttered its operations in 2024. A Google search shows that the distillery is temporarily closed, but little else has been revealed about its future. Stoli Group USA, which produced the award-winning Kentucky Owl whiskey brand, filed for bankruptcy last year, as reported in great detail by Whiskey Advocate here. In a statement to Newsweek , the Distilled Spirits Council shared that the shakeup occuring right now for the Kentucky whiskey business has hit spirits producers of all sorts, hampered by rising costs for materials to produce the priduct, a drop in sales since the boom of the COVID-19 pandemic, and the looming threat of President Donald Trump's tariff policies that have halted trade and export between Canada and other nations that often purchase American spirits in bulk. — Photo: SEE ALSO Whiskey Industry Shifts In Kentucky, With Some Distillers Declaring Bankruptcy was originally published on
